TY  - JOUR
AU  - Northcott, Paul A
AU  - Pfister, Stefan
AU  - Jones, David
TI  - Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies.
JO  - The lancet  / Oncology
VL  - 16
IS  - 6
SN  - 1470-2045
CY  - London
PB  - The Lancet Publ. Group
M1  - DKFZ-2017-03253
SP  - e293 - e302
PY  - 2015
AB  - Arguably, nowhere has there been a greater advance in our understanding of biological mechanisms and potential translational targets during the next-generation sequencing era than in paediatric brain tumours. The so-called omics revolution, enabled by high-throughput sequencing, has empowered large consortia and independent groups alike to make major genetic discoveries, from dominant-negative histone mutations and hijacking of distal enhancer elements, to new oncogenic gene fusions and aberrantly active gene expression. Epigenetic deregulation has also been revealed as a common theme across several tumour subtypes. This Review focuses on key findings that have been transforming the landscape of paediatric neuro-oncology research and how these results are opening new avenues towards potential therapeutic translation.
KW  - Neoplasm Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:26065614
DO  - DOI:10.1016/S1470-2045(14)71206-9
UR  - https://inrepo02.dkfz.de/record/127228
ER  -